From pharmacy counters to rebate contracts—why patients are still the only ones in the dark

How hidden incentives in pharmaceutical rebates quietly reshape what patients pay and what they don’t see

“Big mistake. Huge.”

The beauty of that famous Pretty Woman scene is that everyone knows exactly who lost.

The store lost.

The salesperson lost.

Julia Roberts won.

The incentives were visible.

The salesperson had a financial interest in making a sale. The customer knew she was being sold to. Nobody was pretending otherwise.

Now imagine a transaction where the customer has no idea who’s winning.

The manufacturer gets paid.

The middleman gets paid.

The plan may get paid.

But the person taking the medication doesn’t even know the arrangement exists.

That’s not a shopping problem.

That’s a healthcare problem.

And it’s one of the reasons I’ve spent years asking uncomfortable questions about pharmaceutical rebates.

Years ago, we decided doctors should not be financially rewarded for prescribing specific medications. We recognized the conflict that created.

The logic was simple.

When a physician recommends a treatment, patients should be able to trust that recommendation is based on what’s best for their health—not what’s best for someone’s wallet.

Most people would agree with that principle.

So those arrangements were prohibited.

But here’s the question I can’t stop asking:

Did we eliminate the incentive?

Or did we simply move it?

Today, pharmaceutical manufacturers pay billions of dollars in rebates tied to formulary placement and market share.

For those who don’t spend their days buried in healthcare jargon, a formulary is essentially the preferred list of drugs covered by a health plan.

The industry often argues that rebates lower costs.

But let’s think about that for a minute.

If I walk into a store looking for a black dress, I expect the salesperson to show me the dress that best fits my needs and budget.

What I don’t expect is for the salesperson to steer me toward the most expensive dress because it earns them the biggest commission.

And—try as she may—I KNOW what I can and cannot afford.

I can look at the price tag.

I can decide whether it’s worth it.

I can walk away.

Especially if that commission doesn’t mean I’m getting a better price myself.

Yet that is the uncomfortable question rebates raise.

Why are the largest rebates often associated with the drugs carrying the highest list prices?

Why does a system designed to lower costs depend on higher prices existing in the first place?

The math doesn’t math.

A drug with a $1,000 price tag and a $400 rebate still started at $1,000.

A drug priced at $600 with no rebate may actually cost less, but it doesn’t generate the same financial reward for the parties negotiating the rebate.

And that’s where incentives matter.

Because incentives influence behavior.

They always have.

The problem isn’t that companies make money.

The problem is when financial incentives become disconnected from the interests of the patient.

The patient doesn’t care about rebate guarantees.

The patient doesn’t care about rebate aggregation.

The patient doesn’t care about market-share contracts.

The patient cares about one thing:

Can I get the medication I need at a price I can afford?

Yet too often, the person standing at the pharmacy counter is the only participant in the transaction who doesn’t know who is being paid behind the scenes.

Think about that.

The patient may be paying coinsurance based on the drug’s list price.

The patient may be struggling to afford their medication.

The patient may abandon treatment altogether because of cost.

Meanwhile, financial transactions are occurring throughout the supply chain that the patient never sees and rarely understands.

And somehow we’ve accepted that as normal.

I haven’t.

Because healthcare isn’t a luxury handbag.

Healthcare isn’t a pair of shoes.

Healthcare isn’t a commission-based sales floor.

It’s cancer treatment.

It’s insulin.

It’s medication for a child with ADHD.

It’s treatment for depression.

It’s a grandmother trying to afford the medication that keeps her alive.

When financial incentives exist in healthcare, they should move us closer to better patient outcomes, lower costs, and greater access.

Not create situations where the highest-priced option generates the largest financial reward.

I am not anti-profit.

I am not anti-business.

And contrary to what some may assume, I am not even anti-incentive.

I am anti-incentives that benefit everyone except the patient.

Because if the patient isn’t benefiting, then we need to ask a very simple question:

Who is the system actually working for?

And if we don’t like the answer, maybe it’s time to stop defending the incentives and start defending the patient.

Because the biggest mistake isn’t that someone is making money.

The biggest mistake is pretending the patient is the center of the system while rewarding everyone around them first.

Now that’s a mistake.

Huge